Condition (MeSH)
Myasthenia Gravis, Autoimmune, Experimental
ClinicalTrials.gov lists 2 trials for Myasthenia Gravis, Autoimmune, Experimental or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section
5 sections measured, none recorded · 1 not measured yet · 1 not computed
2 of the 2 trials are tagged with Myasthenia Gravis, Autoimmune, Experimental itself; the rest are tagged with a narrower condition beneath it.
When did Myasthenia Gravis, Autoimmune, Experimental trials start? (2)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
| Year | Trials started |
|---|---|
| 2022 | 1 |
| 2021 | 1 |
No forecast is made for this condition: it averages 0.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 2 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Myasthenia Gravis, Autoimmune, Experimental trials in? (1)
Shown in this order: phase order.
| Phase | Trials |
|---|---|
| Not applicable | 2 |
How many Myasthenia Gravis, Autoimmune, Experimental trials are recruiting? (2)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Completed | 1 |
| Unknown status | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which publications cover Myasthenia Gravis, Autoimmune, Experimental? (5)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Metformin attenuates autoimmune disease of the neuromotor system in animal models of myasthenia gravis. | International immunopharmacology | 2019 | Yes |
| The role of complement in experimental autoimmune myasthenia gravis. | Annals of the New York Academy of Sciences | 2012 | Yes |
| Expansion of regulatory T cells via IL-2/anti-IL-2 mAb complexes suppresses experimental myasthenia. | European journal of immunology | 2010 | Yes |
| Regulatory T cells induced by GM-CSF suppress ongoing experimental myasthenia gravis. | Clinical immunology (Orlando, Fla.) | 2008 | Yes |
| Rational design of peptide vaccines for autoimmune disease: harnessing molecular recognition to fix a broken network. | Expert review of vaccines | 2003 | No |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: lead sponsors, serious adverse events in this condition's trials, prevalence, rare-disease identity, and sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.